NASDAQ: KRSA
Korsana Biosciences Inc Stock

$33.27+0.77 (+2.37%)
Updated Nov 18, 2026
KRSA Price
$33.27
Fair Value Price
$0.38
Market Cap
$1.52B
52 Week Low
$7.19
52 Week High
$59.36
P/E
-2.61x
P/B
3.87x
P/S
422.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.03M
Earnings
-$52.16M
Gross Margin
100%
Operating Margin
-5,088.39%
Profit Margin
-5,088.4%
Debt to Equity
0.12
Operating Cash Flow
-$51M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

KRSA Overview

Korsana Biosciences, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its lead program, KRSA-028, is an investigational shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. The company became publicly traded in September 2026 through a merger with Cyclerion Therapeutics, Inc.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine KRSA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
KRSA
Ranked
#284 of 449

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important KRSA news, forecast changes, insider trades & much more!

KRSA News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KRSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KRSA ($33.27) is overvalued by 8,620.23% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRSA ($33.27) is not significantly undervalued (8,620.23%) relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRSA due diligence checks available for Premium users.

Valuation

KRSA fair value

Fair Value of KRSA stock based on Discounted Cash Flow (DCF)

Price
$33.27
Fair Value
$0.38
Overvalued by
8,620.23%
KRSA ($33.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRSA ($33.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KRSA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.61x
Industry
17.98x
Market
41.36x

KRSA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.87x
Industry
4.91x
KRSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KRSA's financial health

Profit margin

Revenue
$0.0
Net Income
-$46.4M
Profit Margin
0%
KRSA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KRSA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$462.1M
Liabilities
$45.6M
Debt to equity
0.12
KRSA's short-term assets ($460.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRSA's short-term assets ($460.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRSA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KRSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$46.8M
Investing
-$231.0k
Financing
$351.1M
KRSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KRSA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
KRSAD$1.52B+2.37%-2.61x3.87x
MESOC$1.51B-2.27%-26.22x2.66x
KLRAC$1.53B-3.36%N/A1.48x
PGENA$1.53B-0.47%32.85x18.27x
NRIXB$1.54B-0.98%5.64x1.59x

Korsana Biosciences Stock FAQ

What is Korsana Biosciences's quote symbol?

(NASDAQ: KRSA) Korsana Biosciences trades on the NASDAQ under the ticker symbol KRSA. Korsana Biosciences stock quotes can also be displayed as NASDAQ: KRSA.

If you're new to stock investing, here's how to buy Korsana Biosciences stock.

What is the 52 week high and low for Korsana Biosciences (NASDAQ: KRSA)?

(NASDAQ: KRSA) Korsana Biosciences's 52-week high was $59.36, and its 52-week low was $7.19. It is currently -43.95% from its 52-week high and 362.98% from its 52-week low.

How much is Korsana Biosciences stock worth today?

(NASDAQ: KRSA) Korsana Biosciences currently has 45,541,358 outstanding shares. With Korsana Biosciences stock trading at $33.27 per share, the total value of Korsana Biosciences stock (market capitalization) is $1.52B.

Korsana Biosciences stock was originally listed at a price of $1,750.00 in Mar 18, 2019. If you had invested in Korsana Biosciences stock at $1,750.00, your return over the last 7 years would have been -98.1%, for an annualized return of -43.23% (not including any dividends or dividend reinvestments).

How much is Korsana Biosciences's stock price per share?

(NASDAQ: KRSA) Korsana Biosciences stock price per share is $33.27 today (as of Nov 18, 2026).

What is Korsana Biosciences's Market Cap?

(NASDAQ: KRSA) Korsana Biosciences's market cap is $1.52B, as of Nov 19, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Korsana Biosciences's market cap is calculated by multiplying KRSA's current stock price of $33.27 by KRSA's total outstanding shares of 45,541,358.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.